Leukocyte and inflammatory signaling pathway

Leukocyte and inflammatory signaling pathways represent the integrated biological system responsible for detecting and responding to harmful stimuli, such as pathogens or tissue damage [1]. This system encompasses a diverse population of white blood cells, including granulocytes, monocytes, and lymphocytes, which communicate through intricate signaling networks like the NF-κB, JAK-STAT, and MAPK pathways [2][3]. These pathways regulate the production of cytokines, chemokines, and other mediators that orchestrate the inflammatory response [4]. While acute inflammation is protective, chronic activation of these signaling pathways is a primary driver of diseases such as rheumatoid arthritis, inflammatory bowel disease, and atherosclerosis [5]. Pharmacological strategies often target specific nodes within these pathways, such as TNF-alpha or Janus kinases, to mitigate tissue damage [6]. Because this term describes a broad physiological process involving hundreds of distinct proteins, it does not constitute a single therapeutic target but rather a framework for drug discovery [7]. Consequently, therapeutic development focuses on isolating specific receptors or enzymes within this broad category to achieve selective immune modulation [8].

Other names

Immune cell signalingInflammatory cascadesLeukocyte activation pathwaysInflammatory signaling network

Modulation of the inflammatory response through the inhibition of pro-inflammatory cytokines, blockade of leukocyte trafficking to sites of injury, or suppression of intracellular signaling cascades such as the JAK-STAT or NF-κB pathways.